An interventional study of Low FODMAP Diet and Healthy Eating Diet in SIBO, Small Intestinal Bacterial Overgrowth and Small Intestinal Bacterial Overgrowth Syndrome (SIBO), sponsored by Warsaw University of Life Sciences. Completed at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by Warsaw University of Life Sciences · Not applicable, Interventional, and Treatment
This study aims to assess the impact of a low FODMAP diet (LFD) on gastrointestinal symptoms and nutritional status in individuals diagnosed with small intestinal bacterial overgrowth (SIBO). Participants were randomly assigned to either an intervention group or a control group following completion of antibiotic therapy. The intervention group followed a LFD, while the control group followed a normal diet, in accordance with the principles of rational nutrition. Gastrointestinal symptoms, nutritional status, and quality of life were assessed using questionnaires, dietary records, anthropometric measurements, and blood biochemical parameters.
11 studies on the registry are indexed under Blind Loop Syndrome; 4 are open to participants now.
This study's enrollment of 51 is close to the median of 48 across 10 interventional studies indexed under Blind Loop Syndrome.
Browse Blind Loop Syndrome studies →Warsaw University of Life Sciences is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with SIBO who followed a low FODMAP diet after completion of antibiotic therapy.
Other: Low FODMAP Diet
Participants diagnosed with SIBO who followed a diet consistent with the principles of healthy eating after completion of antibiotic therapy.
Other: Healthy Eating Diet
Following a low FODMAP diet (elimination and reintroduction phases for 4 and 8 weeks, respectively, for a total of 12 weeks)
Applying recommendations consistent with proper nutrition principles, with particular focus on breaks between meals and the principle of mindful eating
Gastrointestinal Adverse Symptoms Assessment Questionnaire (GASAQ) total score
Change in gastrointestinal symptom severity assessed using the Gastrointestinal Adverse Symptoms Assessment Questionnaire (GASAQ). The total score ranges from 0 to 100 points, with higher scores indicating more severe gastrointestinal symptoms. Assessments were performed at baseline and after the dietary intervention.
Time frame: 12 weeks
Nutritional status - Mini Nutritional Assessment (MNA)
Change in nutritional status assessed using the Mini Nutritional Assessment (MNA) questionnaire. The total score ranges from 0 to 30 points, with higher scores indicating better nutritional status. Assessments were performed at baseline and after the dietary intervention.
Time frame: 12 weeks
Nutritional status - Blood biochemical parameters (Serum vitamin D concentration)
Change in serum vitamin D levels measured in ng/mL at baseline and after the dietary intervention.
Time frame: 12 weeks
Nutritional status - Blood biochemical parameters (Serum folate concentration)
Change in serum folate levels measured in ng/mL at baseline and after the dietary intervention.
Time frame: 12 weeks
Nutritional status - Blood biochemical parameters (Iron status parameters)
Change in serum iron concentration (µg/dL) measured at baseline and after the dietary intervention.
Time frame: 12 weeks
Nutritional status - Blood biochemical parameters (Serum albumin concentration)
Change in serum albumin levels measured in g/L at baseline and after the dietary intervention.
Time frame: 12 weeks
Nutritional status - Anthropometric parameters (body weight)
Change in body weight (kg) measurements at baseline and after the dietary intervention.
Time frame: 12 weeks
Nutritional status - Anthropometric parameters (body mass index (BMI)
Change in BMI (kg/m²) at baseline and after the dietary intervention. BMI calculated from measured body weight and height (kg/m²).
Time frame: 12 weeks
Nutritional status - anthropometric parameters (body fat percentage)
Change in body fat percentage (%) at baseline and after the dietary intervention. Body fat percentage measured using bioelectrical impedance analysis (ACCUNIQ BC720).
Time frame: 12 weeks
Quality of life - IBS-specific (Irritable Bowel Syndrome-Quality of Life (IBS-QOL) total score)
Change in quality of life assessed using the Irritable Bowel Syndrome-Quality of Life (IBS-QOL) questionnaire. Scores range from 0 to 100 points, with higher scores indicating better quality of life. Assessments were performed at baseline and after the dietary intervention.
Time frame: 12 weeks
Quality of Life - General (Short Form-36 Health Survey (SF-36) total score)
Change in general quality of life assessed using the Short Form-36 Health Survey (SF-36), Polish version. Scores range from 0 to 100 points, with higher scores indicating better perceived health status. Assessments were performed at baseline and after the dietary intervention.
Time frame: 12 weeks
Plan to share: No — The study will not share individual participant data to protect participant confidentiality and privacy.
No publications or documents are linked to this record.
Ran from Feb 2024 to primary completion in Sep 2025, 19 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Warsaw University of Life Sciences